IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Biotechnology

Healthcare
$26.17 -1.45%

-$0.45 today

Market cap
$2.53B
Beta
-0.05
P/E (TTM)
-19.5
EPS (TTM)
-$1.58
52W Low $20.50High $39.28

Volume 1.42M

Average 1.44M

Returns on capital

IDEAYA Biosciences, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-11.1%

avg -0.2%

ROIC

-15.2%

avg -32.2%

ROA

-10.2%

avg -25.8%

Analysis

ROA is currently the strongest return metric at -10.2% versus its period average of -25.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Yujiro S. Hata

Founder, President, CEO & ChairmanUSD 1.09M5223.12K0.02%

Darrin Beaupre

Chief Medical OfficerUSD 738.3K59175.00K0.18%

Michael A. White

President of Research & DevelopmentUSD 728.3K61——

Joshua Bleharski

Chief Financial OfficerUSD 683.35K51170.00K0.18%

Douglas Snyder

Chief Legal OfficerUSD 668.52K62——

Andres Ruiz Briseno

Chief Accounting OfficerUSD 600.8K4019.20K0.02%

Stuart Dorman

Chief Commercial OfficerUSD 161.82K48155.00K0.16%

Jasgit Sachdev

Senior Vice President of Late Phase Clinical Development & Strategy————

Paul A. Barsanti

Chief Technology Officer————

Daniel A. Simon

Chief Business Officer————

Mick O'Quigley

Senior Vice President of Medical Writing & Project Management————

Francine Zelaya

Senior VP & Head of Human Resources————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 6, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$1.65M

Sells

3

$1.37M

Net Transaction Value

+$280,362.43

Net buying

Most Active

Hata Yujiro S

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 6, 26

Hata Yujiro S

Direct

Sell$30.6K
Oct 6, 26

Hata Yujiro S

Direct

Sell$954.8K
Jul 7, 26

Ruiz Briseno Andres

Direct

Sell$382.1K
Mar 2, 26

Stein Jeffrey

Direct

Buy$1.6M

Summary

Insiders reported 1 buys worth $1.65M and 3 sells worth $1.37M over the last 12 months. That adds up to net buying of $280,362.43. Hata Yujiro S was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/A+62.5%
+31.8% (5yr)6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Recent growth has been strongest in Revenue at +62.5% over three years. Forward estimates point to Revenue at +31.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does IDEAYA Biosciences, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about IDYA's management, answered from reported figures.

Who manages IDYA?

IDEAYA Biosciences, Inc. (IDYA) lists 12 active executives. The top listed executive is Jasgit Sachdev, Senior Vice President of Late Phase Clinical Development & Strategy.

Are IDYA insiders buying or selling?

Recent insider activity shows net buying of $136.29M.